Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer

• Published in: International journal of radiation oncology, biology, physics Vol. 109; no. 5; pp. 1301 - 1310
• Main Authors: Clasen, Suparna C., Shou, Haochang, Freedman, Gary, Plastaras, John P., Taunk, Neil K., Kevin Teo, Boon-Keng, Smith, Amanda M., Demissei, Biniyam G., Ky, Bonnie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2021
• Subjects: Adult; Anthracyclines - pharmacology; Antineoplastic Agents - pharmacology; Echocardiography; Female; HEART; Heart - diagnostic imaging; Heart - drug effects; Heart - radiation effects; Humans; Longitudinal Studies; MAMMARY GLANDS; METRICS; Middle Aged; NEOPLASMS; PATIENTS; Prospective Studies; Radiation Dosage; RADIATION DOSES; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Stroke Volume - drug effects; Stroke Volume - radiation effects; Time Factors; Trastuzumab - pharmacology; Unilateral Breast Neoplasms - diagnostic imaging; Unilateral Breast Neoplasms - drug therapy; Unilateral Breast Neoplasms - radiotherapy; Ventricular Function, Left - drug effects; Ventricular Function, Left - radiation effects
• ISSN: 0360-3016; 1879-355X; 1879-355X
• DOI: 10.1016/j.ijrobp.2020.12.008

To characterize the early changes in echocardiographically derived measures of cardiac function with contemporary radiation therapy (RT) in breast cancer and to determine the associations with radiation dose-volume metrics, including mean heart dose (MHD). In a prospective longitudinal cohort study of 86 patients with breast cancer treated with photon or proton thoracic RT, clinical and echocardiographic data were assessed at 3 time points: within 4 weeks before RT initiation (T0), within 3 days before 6 weeks after the end of RT (T1), and 5 to 9 months after RT completion (T2). Associations between MHD and echocardiographically derived measures of cardiac function were assessed using generalized estimating equations to define the acute (T0 to T1) and subacute (T0 to T2) changes in cardiac function. The median estimates of MHD were 139 cGy (interquartile range, 99-249 cGy). In evaluating the acute changes in left ventricular ejection fraction (LVEF) from T0 to T1, and accounting for the time from RT, age, race, preexisting cardiovascular disease, and an interaction term with anthracycline or trastuzumab exposure and MHD, there was a modest decrease in LVEF of borderline significance (0.22%; 95% confidence interval [CI], –0.44% to 0.01%; P = .06) per 30-day interval for every 100 cGy increase of MHD. Similarly, there was a modest worsening in longitudinal strain (0.19%; 95% CI, –0.01% to 0.39%; P = .06) per 30-day interval for each 100 cGy increase in MHD. We did not find significant associations between MHD and changes in circumferential strain or diastolic function. With modern radiation planning techniques, there are modest subclinical changes in measures of cardiac function in the short-term. Longer-term follow-up studies are needed to determine whether these early changes are associated with the development of overt cardiac disease.